SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031), covering 2019-07-24 to 2019-07-24. Get the full timeline:
Most recent: Clinical Trial Update: SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) [Phase 2, Phase 3]